Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00207740 · ClinicalTrials.gov registry record · Phase 2
A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma
A Phase 2 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 2
- Development phase
- 309
- Enrollment target
NCT00207740 is a Phase 2 study that has completed, run by Centocor. The registered enrollment target is 309 participants.
The verdict
NCT00207740, a Phase 2 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 309 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness and safety of CNTO 148 (golimumab) in patients with severe persistent asthma.
Interventions
- DRUG Placebo
- DRUG CNTO148
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 309 participants |
| Start Date | 2004-08 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00207740
The ClinicalTrials.gov registry entry for NCT00207740 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 309 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00207740 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00207740 about?
NCT00207740 is a clinical study titled "A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma". The purpose of this study is to evaluate the effectiveness and safety of CNTO 148 (golimumab) in patients with severe persistent asthma.
What is the current status of trial NCT00207740?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 309 participants. The study started on 2004-08. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00207740?
The interventions under investigation include: Placebo (DRUG), CNTO148 (DRUG).
Who is sponsoring clinical trial NCT00207740?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.